p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis

International Journal of Cancer

Volumn 114, Issue 3, 2005, Pages 331-336

  Tsang, Wing Pui ^a   Ho, Franz Y F ^a   Fung, Kwok Pui ^a   Kong, Siu Kai ^a   Kwok, Tim Tak ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Caspase 3; Doxorubicin; p53 mutation

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMINYLMETHIONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 9; CISPLATIN; DNA; DOXORUBICIN; PROCASPASE 3; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME REPRESSION; GAMMA IRRADIATION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NULL ALLELE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BONE NEOPLASMS; CASPASE 3; CASPASES; DOWN-REGULATION; DOXORUBICIN; GENE SILENCING; GENES, P53; HUMANS; MUTATION, MISSENSE; OSTEOSARCOMA; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 14044268786     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20818     Document Type: Article

References (24)

1. Li PF, Dietz R, Harsdorf RV. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999;18:6027-36.
2. Miyashita T, Reed JC. The tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995;80:293-9.
3. Owen-Scaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cel Biol 1995;15:3032-40.
4. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Dao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
5. Harris C. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-9.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
7. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57.
8. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-542.
9. Tweddle D, Malcolm A, Bown N, Pearson A, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001;61:8-13.
10. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998;16:3269-77.
11. Chang EH, Jang YJ, Hao Z, Murphy G, Rait A, Fee WE Jr, Sussman HH, Ryan R, Chiang Y, Pirollo KF. Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Arch Otolaryngol Head Neck Surg 1997;123:507-12.
12. Scott SL, Earle JD, Gumerlock PH. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res 2003;63:7190-6.
13. Cui HJ, Schroering A, Ding HF. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Can Ther 2002;1:679-86.
14. Stahler F, Roemer K. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 1998;17:3507-12.
15. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
16. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-response genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
17. De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS. Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J Biol Chem 2003;278:11086-93.
18. Murphy KL, Dennis AP, Rosen JM. A gain of function of p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 2000;14:2291-302.
19. Liu WF, Wang GP, Yakovlev AG. Identification and functional analysis of the rat casepase-3 gene promotor. J Biol Chem 2002;277:8273-8.
20. Wang Q, Back WT. Transcriptional suppression of multidrug resistance-associated (MRP) gene expression by wild-type p53. Cancer Res 1998;58:5762-9.
21. Chen L, Woo M, Hakem R, Miller RG. Perforin-dependent activation-induced cell death acts through caspase-3 but not through caspase-8 or 9. Eur J Immunol 2003;33:769-78.
22. Stennicke, HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salvesen GS. Caspase-9 can be activated without proteolytic processing. J Biol Chem 1999;274:8359-62.
23. Atkinson EA, Barry M, Darmon AJ, Shostak I, Turner PC, Moyer RW, Bleackley RC. Cytotoxic T lymphocyte-assisted suicide. Caspase-3 activation is primarily the result of the direct action of granzyme B. J Biol Chem 1998;273:21261-6.
24. Kingham PJ, Pocock JM. Microglial secreted cathepsin B induces neuronal apoptosis. J Neurochem 2001;76:1475-84.